simvastatin has been researched along with Esophageal Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Fullerton, DA; Gergen, AK; Li, A; Madsen, HJ; Meng, X; Pratap, A; Weyant, MJ | 1 |
| Beer, DG; Chang, AC; Ferrer-Torres, D; Hinton, T; Jiang, H; Lagisetty, K; Lawrence, TS; Lin, J; Nancarrow, D; Owens, S; Ray, D; Ray, P; San Martinho, M; Thomas, D; Wang, Z; Yoon, HW | 1 |
| Alexandre, L; Cheong, EC; Clark, AB; Dresner, SM; Flather, M; Hammond, M; Hart, AR; Jones, M; Kadirkamanathan, SS; Kumar, B; Lewis, MP; Loke, YK; Parsons, SL; Sims, E; Swart, AM; Walton, S; Warren, H | 1 |
| Fullerton, DA; Gergen, AK; Halpern, AL; Kohtz, PD; Meng, X; Weyant, MJ; White, AM | 1 |
| Chen, Q; Huang, S; Jin, Y; Ma, H; Pan, J; Wang, B; Wei, Y; Xu, K | 1 |
| Chen, Y; Li, LB; Tang, DP; Wei, JJ; Zhang, J; Zhuang, ZH | 1 |
| Backman, JT; Calfee, CS; Duffy, MJ; Elborn, SJ; Griffiths, MJ; Johnston, JR; MacSweeney, R; Matthay, MM; McAuley, DF; McDowell, C; McGuigan, J; OʼKane, CM; Shields, MO; Shyamsundar, M | 1 |
| Battersby, CL; Bryan, N; Hunt, JA | 1 |
| McAuley, DF; O'Kane, CM; Shyamsundar, M | 1 |
| Dhayat, S; Mehdorn, AS; Palmes, D | 1 |
| Duan, Z; El-Serag, HB; Kramer, JR; Naik, AD; Nguyen, T | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Burnat, G; Hahn, EG; Konturek, PC | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Hawk, ET; Viner, JL | 1 |
2 trial(s) available for simvastatin and Esophageal Neoplasms
| Article | Year |
|---|---|
Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Quality of Life; Simvastatin; Treatment Outcome; United Kingdom | 2020 |
Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial.
Topics: Acute Lung Injury; Aged; Double-Blind Method; Endothelium; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pulmonary Alveoli; Simvastatin | 2014 |
13 other study(ies) available for simvastatin and Esophageal Neoplasms
| Article | Year |
|---|---|
Simvastatin Inhibits Histologic Changes Associated with Gastroduodenal Reflux in a Murine Model.
Topics: Adenocarcinoma; Animals; Annexin A5; Barrett Esophagus; Caspase 3; Disease Models, Animal; Esophageal Neoplasms; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Simvastatin | 2022 |
Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Cells, Cultured; Down-Regulation; Esophageal Neoplasms; Esophagus; Female; Gene Expression; Gene Silencing; Glycosylation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Signal Transduction; Simvastatin; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2020 |
Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Animals; Atorvastatin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Random Allocation; Signal Transduction; Simvastatin; Toll-Like Receptor 4; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway.
Topics: Cell Line, Tumor; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Radiation Tolerance; Signal Transduction; Simvastatin | 2018 |
Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation; Humans; Pravastatin; Simvastatin | 2018 |
Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial.
Topics: Acute Lung Injury; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin | 2015 |
Reply to Letter: "Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial".
Topics: Acute Lung Injury; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin | 2015 |
Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy.
Topics: Acute Lung Injury; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin | 2015 |
Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Topics: Adenocarcinoma; Adult; Aged; Barrett Esophagus; Case-Control Studies; Chemoprevention; Dose-Response Relationship, Drug; Esophageal Neoplasms; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Logistic Models; Male; Middle Aged; Neoplasm Staging; Pharmacoepidemiology; Risk Assessment; Simvastatin; United States; Veterans | 2015 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Barrett Esophagus; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dose-Response Relationship, Drug; Esophageal Neoplasms; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2007 |
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Apoptosis; Barrett Esophagus; Caspase 3; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lovastatin; Mevalonic Acid; Nitrobenzenes; Polyisoprenyl Phosphates; Pravastatin; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Simvastatin; Sulfonamides | 2008 |
Statins in esophageal cancer cell lines: promising lead?
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 2008 |